Company attributes
Other attributes
Tevard Biosciences was founded in 2017 by Daniel Fischer and Warren Lammert, parents of girls with Dravet Syndrome, and Harvey Lodish, a professor at MIT and Whitehead Institute for Biomedical Research.
Tevard Biosciences is developing gene therapy platforms to target rare diseases such as Dravet syndrome and disorders caused by haploinsufficiency and/or premature stop codons, which traditional gene therapy approaches do not target. Dravet syndrome is also known as Severe Myoclonic Epilepsy of Infancy (SMEI), a condition caused by a mutation in the SCN1A gene required for brain cell function, in 85% of cases.
The company is housed at LabCentral, a shared laboratory space for launching life sciences and biotech start-ups. Tevard Biosciences won a Pfizer-sponsored LabCentral “Golden Ticket” in 2018, which provides one year of bench space for one scientist with infrastructure and services.
